Product Code: MCP13704
Global Oncology Molecular Diagnostics Market to Reach US$3.6 Billion by the Year 2027
Amid the COVID-19 crisis, the global market for Oncology Molecular Diagnostics estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$3.6 Billion by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027.Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 8.7% CAGR to reach US$900.3 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period. This segment currently accounts for a 25.8% share of the global Oncology Molecular Diagnostics market.
The U.S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 14.9% CAGR for the Period of 2020-2027
The Oncology Molecular Diagnostics market in the U.S. is estimated at US$490.5 Million in the year 2020. The country currently accounts for a 28.84% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$669.6 Million in the year 2027 trailing a CAGR of 14.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR while Rest of European market (as defined in the study) will reach US$669.6 Million by the year 2027.
Prostate Cancer Segment Corners a 18.2% Share in 2020
In the global Prostate Cancer segment, USA, Canada, Japan, China and Europe will drive the 11.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$233.6 Million in the year 2020 will reach a projected size of US$506.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$533.5 Million by the year 2027, while Latin America will expand at a 14% CAGR through the analysis period. We bring years of research experience to this 7th edition of our report. The 287-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others,
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
- Leica Biosystems Inc.
- Qiagen NV
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers
- Sysmex Corporation
TABLE OF CONTENTS
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
- Global Competitor Market Shares
- Oncology Molecular Diagnostics Competitor Market Share Scenario Worldwide (in %): 2018E
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 2: World Historic Review for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 3: World 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027
- TABLE 4: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 6: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 7: World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 8: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 9: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 10: World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 11: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 12: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 13: World Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 14: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 15: World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 16: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 17: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 18: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 19: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 20: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 21: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 22: World Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 23: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 24: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- TABLE 25: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 26: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 27: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
III. MARKET ANALYSIS
- GEOGRAPHIC MARKET ANALYSIS
- UNITED STATES
- Market Facts & Figures
- US Oncology Molecular Diagnostics Market Share (in %) by Company: 2018 & 2027
- Market Analytics
- TABLE 28: USA Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 29: USA Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 30: USA 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 31: USA Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 32: USA Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 33: USA 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- CANADA
- TABLE 34: Canada Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 35: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 36: Canada 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 37: Canada Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 38: Canada Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 39: Canada 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- JAPAN
- TABLE 40: Japan Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 41: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 42: Japan 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 43: Japan Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 44: Japan Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 45: Japan 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- CHINA
- TABLE 46: China Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 47: China Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 48: China 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 49: China Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 50: China Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 51: China 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- EUROPE
- Market Facts & Figures
- European Oncology Molecular Diagnostics Market: Competitor Market Share Scenario (in %) for 2018 & 2027
- Market Analytics
- TABLE 52: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 53: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 54: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2018 & 2027
- TABLE 55: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 56: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 57: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 58: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 59: Europe Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 60: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- FRANCE
- TABLE 61: France Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 62: France Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 63: France 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 64: France Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 65: France Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 66: France 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- GERMANY
- TABLE 67: Germany Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 68: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 69: Germany 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 70: Germany Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 71: Germany Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 72: Germany 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- ITALY
- TABLE 73: Italy Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 74: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 75: Italy 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 76: Italy Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 77: Italy Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 78: Italy 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- UNITED KINGDOM
- TABLE 79: UK Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 80: UK Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 81: UK 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 82: UK Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 83: UK Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 84: UK 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- SPAIN
- TABLE 85: Spain Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 86: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 87: Spain 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 88: Spain Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 89: Spain Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 90: Spain 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- RUSSIA
- TABLE 91: Russia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 92: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 93: Russia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 94: Russia Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 95: Russia Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 96: Russia 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- REST OF EUROPE
- TABLE 97: Rest of Europe Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 98: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 99: Rest of Europe 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 100: Rest of Europe Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 101: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 102: Rest of Europe 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- ASIA-PACIFIC
- TABLE 103: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 104: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 105: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027
- TABLE 106: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 107: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 108: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 109: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 110: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 111: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- AUSTRALIA
- TABLE 112: Australia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 113: Australia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 114: Australia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 115: Australia Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 116: Australia Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 117: Australia 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- INDIA
- TABLE 118: India Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 119: India Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 120: India 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 121: India Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 122: India Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 123: India 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- SOUTH KOREA
- TABLE 124: South Korea Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 125: South Korea Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 126: South Korea 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 127: South Korea Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 128: South Korea Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 129: South Korea 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- REST OF ASIA-PACIFIC
- TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 131: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 133: Rest of Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 134: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 135: Rest of Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- LATIN AMERICA
- TABLE 136: Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 137: Latin America Historic Review for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 138: Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2018 & 2027
- TABLE 139: Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 140: Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 141: Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 142: Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 143: Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 144: Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- ARGENTINA
- TABLE 145: Argentina Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 146: Argentina Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 147: Argentina 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 148: Argentina Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 149: Argentina Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 150: Argentina 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- BRAZIL
- TABLE 151: Brazil Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 152: Brazil Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 153: Brazil 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 154: Brazil Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 155: Brazil Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 156: Brazil 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- MEXICO
- TABLE 157: Mexico Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 158: Mexico Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 159: Mexico 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 160: Mexico Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 161: Mexico Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 162: Mexico 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- REST OF LATIN AMERICA
- TABLE 163: Rest of Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 164: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 165: Rest of Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 166: Rest of Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 167: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 168: Rest of Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- MIDDLE EAST
- TABLE 169: Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027
- TABLE 170: Middle East Historic Review for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 171: Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2018 & 2027
- TABLE 172: Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 173: Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 174: Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 175: Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 176: Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 177: Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- IRAN
- TABLE 178: Iran Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 179: Iran Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 180: Iran 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 181: Iran Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 182: Iran Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 183: Iran 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- ISRAEL
- TABLE 184: Israel Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 185: Israel Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 186: Israel 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 187: Israel Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 188: Israel Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 189: Israel 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- SAUDI ARABIA
- TABLE 190: Saudi Arabia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 191: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 192: Saudi Arabia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 193: Saudi Arabia Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 194: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 195: Saudi Arabia 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- UNITED ARAB EMIRATES
- TABLE 196: UAE Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 197: UAE Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 198: UAE 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 199: UAE Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 200: UAE Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 201: UAE 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- REST OF MIDDLE EAST
- TABLE 202: Rest of Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 203: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 204: Rest of Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 205: Rest of Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 206: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 207: Rest of Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
- AFRICA
- TABLE 208: Africa Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 209: Africa Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 210: Africa 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
- TABLE 211: Africa Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027
- TABLE 212: Africa Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017
- TABLE 213: Africa 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
IV. COMPETITION
- Total Companies Profiled: 42
比較リスト
